Dier Mardi

CFO Dier Mardi sold 1,982 shares (2.0K) for $853,992.52 across 12 transactions at blended $430.87

Dier Mardi, EVP and CFO of Madrigal Pharmaceuticals, executed 12 separate sales totaling 1,982 shares for $853,992.52 on 2026-03-06, reducing his holdings by 13.7% from 14,472 to 12,490 shares. The company is currently unprofitable with net income of $-114,190,000.00 against revenue of $287,268,000.00, and the stock has declined 28.2% from its 52-week high of $602.83 and 9.6% over the past 30 days. His prior 4 measurable sales at MDGL were each well-timed at the 90-day mark, with all posting negative 90-day returns (-24.4%, -25.9%, -26.1%, -26.2%) after he sold, demonstrating a consistent pattern of selling before subsequent declines at this specific ticker.

CFO Dier Mardi sold 1,183 shares (1.2K) of MDGL at $427.21; stock down -27.7% from 52-week high and -11.0% in 30 days; unprofitable company with -$114.2M net income

Dier Mardi, EVP and CFO, sold 1,183 shares for $505,389.43 on 2026-03-02, reducing his holdings from 10,440 to 9,257 shares. This sale occurs as MDGL stock has declined -27.7% from its 52-week high of $602.83 and has fallen -11.0% over the past 30 days. Notably, Mardi's prior trades at this ticker show a 5 of 5 perfect timing record on sells—all five prior sales at MDGL on 2025-12-02 were followed by 90-day declines ranging from -25.6% to -26.9%—and his broader cross-ticker track record shows a 100.00% well-timed rate on 17 prior sells, with average 90-day returns of -23.9%. The company remains unprofitable with a net loss of $-114.2M despite impressive revenue growth of +432.0%, creating tension between growth narrative and financial sustainability. The combination of this CFO's historically accurate sell timing at this specific ticker, concurrent downward price pressure, and the company's structural unprofitability warrants attention to whether recent momentum may be reversing.

CFO Dier Mardi sold 4,173 shares ($2.4M) in 15 separate transactions on 2025-12-02; reduces holdings 28.6%

Dier Mardi, EVP and CFO of Madrigal Pharmaceuticals, executed 15 separate sales totaling 4,173 shares for $2,413,416.42 on 2025-12-02, reducing his holdings by 28.6% from 14,613 to 10,440 shares. The multi-tranche structure across a narrow price range ($570.39–$595.20, blended average $578.34) is consistent with a systematic disposition rather than a single-price transaction. This is notable in the context of Madrigal's negative net income of $-114,190,000.00 for the latest quarter and unprofitability over its most recent full fiscal year. His prior two sales at this ticker (both on 2025-03-03) showed 90-day declines of -15.5% and -14.9%, establishing a pattern of well-timed exits at MDGL. Against a 30-day rally of +40.6% and current price of $579.89 (only 3.5% below the 52-week high of $601.03), the timing of this large reduction in equity exposure warrants investor attention.

CFO Dier Mardi sold 1,961 shares across 2 transactions for $637,248.06; post-transaction holdings drop to 6.9K shares (-22.1%)

Dier Mardi, SVP and CFO of Madrigal Pharmaceuticals, executed 2 separate sales totaling 1,961 shares (2.0K shares) for $637,248.06 at an blended average price of $324.96 on 2025-03-03. This sale reduces his holdings by 22.1% from 8,875 shares to 6,914 shares. The company is unprofitable, reporting net income of $-106,964,000.00 for its most recent full fiscal year, while the stock has recovered significantly: currently at $347.28, it sits -2.4% from its 52-week high and has gained 6.7% over the past 30 days and 10.9% over the past 90 days. Mardi's cross-ticker track record shows 3 prior buys with a 100.00% 90-day win rate, though that historical pattern does not apply to his sale activity at this ticker. The sale at a price below current levels, combined with the company's negative profitability backdrop, is a factual transaction requiring investor awareness but does not signal definitive conviction either way without context on equity award schedules or liquidity needs.